Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, has appointed Yajie Li as Chief Medical Officer (CMO). Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

In this role, Li will lead clinical development, regulatory strategy, and medical affairs for the company's clinical-stage programmes. She will also play a key role in evaluating early-stage assets based on unmet medical needs, clinical value, and scientific differentiation.

Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs, including Merck, Johnson and Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China (NMPA)/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas. She holds a master's degree in Rheumatology and Immunology from Peking Union Medical College.

Welcoming Li to their executive team, Dr. Wang, said, “Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world."

"It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth,” Li said, noting that the company's cutting-edge antibody technology platform and global research and development strategy are “well positioned to deliver innovative therapies in areas of high unmet need.”